Kalaris Therapeutics, Inc.
KLRS
$3.41
-$0.06-1.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.89M | 15.34M | 15.40M | 15.04M | 13.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.76M | 47.63M | 46.15M | 42.48M | 67.59M |
| Operating Income | -47.76M | -47.63M | -46.15M | -42.48M | -67.59M |
| Income Before Tax | -44.26M | -44.10M | -43.44M | -55.47M | -81.66M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.26 | -44.10 | -43.44 | -55.47 | -81.66 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.26M | -44.10M | -43.44M | -55.47M | -81.66M |
| EBIT | -47.76M | -47.63M | -46.15M | -42.48M | -67.59M |
| EBITDA | -47.73M | -35.35M | -23.53M | -12.74M | -- |
| EPS Basic | -2.09 | -2.21 | -4.27 | -20.04 | -47.57 |
| Normalized Basic EPS | -1.31 | -1.38 | -2.67 | -12.52 | -29.73 |
| EPS Diluted | -2.09 | -2.21 | -4.27 | -20.04 | -47.57 |
| Normalized Diluted EPS | -1.31 | -1.38 | -2.67 | -12.52 | -29.73 |
| Average Basic Shares Outstanding | 85.68M | 80.58M | 60.91M | 42.81M | 25.46M |
| Average Diluted Shares Outstanding | 85.68M | 80.58M | 60.91M | 42.81M | 25.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |